相关实验视频

Updated: Jun 26, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

在脆弱患者中个性化治疗多发性骨髓瘤

Jodi J Lipof¹, Nadine Abdallah², Brea Lipe³

¹Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA.

Current oncology reports

|May 18, 2024

概括

管理患有多发性骨髓瘤 (MM) 的脆弱患者是具有挑战性的. 三重治疗方案是首选的,临床试验对于新诊断或复发/耐药MM的这个代表性不足的群体至关重要.

科学领域:

血液学血液学血液学
老年瘤学老年瘤学
临床试验设计临床试验设计

背景情况:

多发性骨髓瘤 (MM) 的治疗选择不断扩大,在管理老年和脆弱的患者方面存在挑战.
脆弱的患者在临床试验中往往没有得到充分的代表,这导致对新诊断的 (NDMM) 和复发/耐药性疾病 (RRMM) 的指导有限.

研究的目的:

审查多发性骨髓瘤的脆弱性评估工具.
总结关于NDMM和RRMM的脆弱患者的临床试验数据.
为患有多发性骨髓瘤的脆弱患者提供实际的管理建议.

主要方法:

在过去十年中对临床试验和脆弱性评分工具的文献综述.
对分组数据的分析,重点关注脆弱患者群体.
综合证据以指导脆弱患者的评估和管理.

主要成果:

虚弱是多发性骨髓瘤治疗耐受性和反应的重要预测因素.
对于脆弱的患者来说,三重疗法通常比双重疗法更好.
建议对这一弱势群体优先进行临床试验的招生.

结论:

对患有多发性骨髓瘤的脆弱患者需要有效的评估和管理策略.
临床试验对于收集数据和改善这一代表性不足的群体的结果至关重要.
量身定制的治疗方法,优先考虑三重方案和临床试验参与,可以优化对脆弱患者的护理.

关键词:

脆弱的患者是脆弱的患者.多发性骨髓瘤是一种多发性骨髓瘤.患有骨髓瘤的老年人移植不符合资格.

更多相关视频

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...